|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
260,040,000 |
Market
Cap: |
122.27(B) |
Last
Volume: |
1,971,146 |
Avg
Vol: |
1,608,800 |
52
Week Range: |
$323.62 - $456.95 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ-100 |
|
S&P 400 MIDCAP |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 543 |
Guru Rank Value : 3 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile Vertex Pharmaceuticals is a biotechnology company. Co. has clinical and research programs to develop treatment of cystic fibrosis. In addition, Co. has a pipeline of investigational therapies in other diseases where it is utilizing insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. Co.'s marketed CF medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and KALYDECO (ivacaftor).
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
27,952 |
149,290 |
264,317 |
624,786 |
Total Sell Value |
$12,512,803 |
$62,732,519 |
$104,276,665 |
$212,070,018 |
Total People Sold |
8 |
12 |
14 |
18 |
Total Sell Transactions |
9 |
42 |
65 |
132 |
End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Wagner Charles F Jr |
EVP & Chief Financial Officer |
|
2023-03-13 |
4 |
AS |
$288.31 |
$783,346 |
D/D |
(2,666) |
53,379 |
|
24% |
|
Wagner Charles F Jr |
EVP & Chief Financial Officer |
|
2023-03-10 |
4 |
AS |
$286.64 |
$604,709 |
D/D |
(2,088) |
56,045 |
|
26% |
|
Altshuler David |
EVP, Global Research and CSO |
|
2023-02-27 |
4 |
AS |
$287.23 |
$1,218,449 |
D/D |
(4,238) |
32,038 |
|
18% |
|
Ambrose Kristen |
SVP & Chief Accounting Officer |
|
2023-02-27 |
4 |
AS |
$287.25 |
$347,072 |
D/D |
(1,207) |
7,303 |
|
18% |
|
Tatsis Ourania |
EVP, Chief Reg. & Quality Off. |
|
2023-02-27 |
4 |
AS |
$287.20 |
$101,768 |
D/D |
(354) |
56,805 |
|
18% |
|
Arbuckle Stuart A |
EVP, COO |
|
2023-02-27 |
4 |
AS |
$287.16 |
$1,447,143 |
D/D |
(5,034) |
56,556 |
|
18% |
|
Kewalramani Reshma |
CEO & President |
|
2023-02-24 |
4 |
D |
$289.12 |
$2,713,680 |
D/D |
(9,386) |
129,969 |
|
- |
|
Altshuler David |
EVP, Global Research and CSO |
|
2023-02-24 |
4 |
D |
$289.12 |
$1,147,806 |
D/D |
(3,970) |
36,276 |
|
- |
|
Ambrose Kristen |
SVP & Chief Accounting Officer |
|
2023-02-24 |
4 |
D |
$289.12 |
$145,138 |
D/D |
(502) |
8,510 |
|
- |
|
Tatsis Ourania |
EVP, Chief Reg. & Quality Off. |
|
2023-02-24 |
4 |
D |
$289.12 |
$956,409 |
D/D |
(3,308) |
57,159 |
|
- |
|
Sanna Bastiano |
EVP, Cell & Genetic Therapies |
|
2023-02-24 |
4 |
D |
$289.12 |
$1,147,806 |
D/D |
(3,970) |
52,014 |
|
- |
|
Arbuckle Stuart A |
EVP, COO |
|
2023-02-24 |
4 |
D |
$289.12 |
$1,362,912 |
D/D |
(4,714) |
61,590 |
|
- |
|
Sachdev Amit |
EVP, Chief Patient Officer |
|
2023-02-24 |
4 |
D |
$289.12 |
$713,548 |
D/D |
(2,468) |
66,518 |
|
- |
|
Wagner Charles F Jr |
EVP & Chief Financial Officer |
|
2023-02-24 |
4 |
D |
$289.12 |
$956,409 |
D/D |
(3,308) |
58,133 |
|
- |
|
Bozic Carmen |
EVP and CMO |
|
2023-02-24 |
4 |
D |
$289.12 |
$956,409 |
D/D |
(3,308) |
63,207 |
|
- |
|
Leiden Jeffrey M |
Executive Chairman |
|
2023-02-24 |
4 |
D |
$289.12 |
$3,969,618 |
D/D |
(13,730) |
48,349 |
|
- |
|
Arbuckle Stuart A |
EVP, COO |
|
2023-02-22 |
4 |
AS |
$291.84 |
$706,679 |
D/D |
(2,401) |
66,304 |
|
18% |
|
Arbuckle Stuart A |
EVP, COO |
|
2023-02-21 |
4 |
AS |
$291.01 |
$705,596 |
D/D |
(2,402) |
68,705 |
|
20% |
|
Tatsis Ourania |
EVP, Chief Reg. & Quality Off. |
|
2023-02-21 |
4 |
AS |
$291.01 |
$141,002 |
D/D |
(480) |
60,467 |
|
20% |
|
Altshuler David |
EVP, Global Research and CSO |
|
2023-02-21 |
4 |
AS |
$291.01 |
$1,175,676 |
D/D |
(4,002) |
40,246 |
|
20% |
|
Kewalramani Reshma |
CEO & President |
|
2023-02-17 |
4 |
D |
$292.85 |
$2,740,783 |
D/D |
(9,359) |
139,355 |
|
- |
|
Arbuckle Stuart A |
EVP, COO |
|
2023-02-17 |
4 |
D |
$292.85 |
$1,317,239 |
D/D |
(4,498) |
71,107 |
|
- |
|
Sanna Bastiano |
EVP, Cell & Genetic Therapies |
|
2023-02-17 |
4 |
D |
$292.85 |
$1,098,188 |
D/D |
(3,750) |
55,984 |
|
- |
|
Wagner Charles F Jr |
EVP & Chief Financial Officer |
|
2023-02-17 |
4 |
D |
$292.85 |
$1,098,188 |
D/D |
(3,750) |
61,441 |
|
- |
|
Bozic Carmen |
EVP and CMO |
|
2023-02-17 |
4 |
D |
$292.85 |
$1,098,188 |
D/D |
(3,750) |
66,515 |
|
- |
|
3280 Records found
|
|
Page 8 of 132 |
|
|